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a TunisiaBackground: Anemia on admission is a powerful predictor of major cardiovascular events in patients presenting for
acute coronary syndromes. We sought to determine the prevalence and prognostic impact of anemia in patients
presenting for ST-elevation myocardial infarction (STEMI).
Methods: We analyzed data from a Tunisian retrospective single center STEMI registry. Patients were enrolled
between January 1998 and October 2014. Anemic and nonanemic patients were compared for clinical and prognostic
features and according to four prespecified hemoglobin level subgroups. In patients with severe anemia, factors
associated with in-hospital death were studied.
Results: A total of 1498 patients were enrolled. Mean age was 60.47  12.7 years and prevalence of anemia was
36.6%. Anemic patients were more likely to be elderly, hypertensive, and diabetic in comparison to nonanemic
patients. In-hospital mortality was significantly higher in anemic patients (14.9% vs. 5%, p < 0.001). Lower hemoglo-
bin levels were significantly associated with a higher prevalence of heart failure on admission, cardiogenic shock,
and in-hospital mortality (p < 0.001 for all). In univariate analysis, factors associated with in-hospital death in
patients with severe anemia were hypertension (p = 0.044), heart failure on admission (p < 0.001), renal failure on
admission (p < 0.001), and primary percutaneous coronary intervention (pPCI) use (p = 0.016). The absence of pPCI
use was independently associated with in-hospital death in multivariate analysis (odds ratio = 2.22, 95% confidence
interval: 1.07–4.76, p = 0.033).
Conclusion: According to this study, anemic patients presenting for STEMI have a higher in-hospital mortality
rate. The absence of pPCI use was independently associated with in-hospital death.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
ACS acute coronary syndrome
CCU coronary care unit
CI confidence interval
CKD chronic kidney disease
HF heart failure
HORIZONS-AMI Harmonizing Outcomes with Revascular-
ization and Stents in Acute Myocardial Infarction
MDRD Modification of Diet in Renal Disease
OPTIMAAL Optimal Trial in Myocardial Infarction with the
Angiotensin II Antagonist Losartan
OR odds ratio
pPCI primary percutaneous coronary intervention
SPSS statistical package for social sciences
STEMI ST-elevation myocardial infarction
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Anemia at presentation and during hospitalstay is reported to be highly predictive of
poor in-hospital and long-term outcomes in
patients presenting with acute coronary syn-
dromes (ACS) [1–4]. In several reports, baseline
hemoglobin level was proven to be correlated to
the incidence of in-hospital complications in
patients treated for ST-elevation myocardial
infarction (STEMI) [5–7]. Furthermore, blood
transfusion is a frequently utilized therapeutic in
this setting and was nevertheless proven to be
another predictor of adverse events in patients
hospitalized for ACS [8,9].
Aside from hemoglobinopathies in the younger
demographic, iron-deficiency accounts for the
majority of anemia cases in the adult population
in the Middle East and North Africa [10–12]. In
addition, it is also known that the epidemiology
of STEMI with regards to patients risk profile
and management strategies implemented are
quite different in these parts of the world when
compared to those in Western countries. In many
of these countries, indeed, the implementation of
primary percutaneous coronary intervention
(pPCI) for the management of STEMI is still not
the default strategy and an evaluation of the
impact of anemia at presentation on outcomes,
especially in relation to the management strate-
gies adopted, is warranted. No data from the
North African countries are available.
In this study, we sought to investigate the
prevalence and the prognostic significance of
anemia on admission in patients presenting with
STEMI in a Tunisian tertiary care center, particu-
larly in relation to therapeutic strategies utilized
in this context.2. Materials and methods
2.1. Population and study design
The present study was led on data from the
STEMI registry of Cardiology B Department, Fat-
touma Bourguiba University Hospital (Monastir,
Tunisia). The registry enrolls in a yearly fashion
all patients agedP18 years presenting to our cen-
ter for STEMI, regardless of the management
strategy adopted. The study performed is a retro-
spective observational study on all consecutive
patients admitted to our department between Jan-
uary 1998 and October 2014. Patients are referred
to our department from the emergency ward or
the local Emergent Medical Aid system. The diag-Please cite this article in press as: Jomaa W. et al., Prevalence and prog
myocardial infarction in a Tunisian center, J Saudi Heart Assoc (2016), httnosis of STEMI was established in the presence of
a significant ST-segment elevation (1 mm in fron-
tal leads and 2 mm in precordial leads) in two
adjacent leads, or a presumably new left bundle
branch block concomitantly to a persistent
(>20 minutes) chest discomfort. In our practice,
the decision to perform pPCI, thrombolysis, or
not to opt for a reperfusion therapy is undertaken
as in accordance as possible with the European
Society guidelines [13], while taking into account
the ischemic-hemorrhagic balance for each reper-
fusion modality, implementation delays, and the
patient clinical background. Reasons for manag-
ing patients conservatively (i.e., without reperfu-
sion) were diverse (late presentation, advanced
age, etc.). All patients received intravenously
100 UI/kg of weight unfractionated heparin upon
diagnosis, 250 mg aspirin and a 300-mg or 600-
mg loading dose of clopidogrel according to the
reperfusion strategy chosen (thrombolysis or
pPCI).
Clinical history and cardiovascular risk factors
were collected upon presentation and at 24 hours.
Initial physical examination was reported. Blood
samples were retrieved upon admission for blood
cell count and other standard analyses. Anemia
was defined according to the World Health Orga-
nization criteria (hemoglobin <13 g/dL in men and
<12 g/dL in women) [14]. Severe anemia was
defined by a hemoglobin rate <11 g/dL. Anemic
and nonanemic patients were first compared
regarding clinical characteristics, management,
and in-hospital complications and mortality; the
study population was then split into four prespec-
ified subgroups according to baseline hemoglobin
levels (P16 g/dL, 13.5–15.9 g/dL, 11–13.4 g/dL, and
<11 g/dL) to better analyze trends in clinical and
prognostic features according to the hemoglobin
subgroup. Heart failure (HF) on admission wasnostic significance of anemia in patients presenting for ST-elevation
p://dx.doi.org/10.1016/j.jsha.2016.10.003
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ANEMIA IN STEMIdefined by a Killip II or Killip III class. Killip IV
class was referred to as cardiogenic shock. Renal
failure on admission was defined as a creatinine
clearance <45 mL/min using the Modification of
Diet in Renal Disease formula in patients not pre-
viously known to suffer from chronic kidney dis-
ease (CKD); in patients known to have CKD,
renal failure on admission was defined as an
increase of P30% of baseline serum creatinine
rate. Bleeding complications were defined as
any overt or nonovert bleeding with a drop of
P2 g/dL in hemoglobin or needing blood transfu-
sion. In patients with severe anemia, relevant fac-
tors associated with in-hospital death were
studied in univariate then in multivariate analysis.2.2. Statistical analysis
Continuous variables were presented as
means  standard deviation. Categorical variables
are presented as absolute values and percentages.
When appropriate, the chi-square test was
applied to compare proportions between anemic
and nonanemic patients and between the four
prespecified hemoglobin subgroups. It was also
applied to determine factors associated with in-
hospital death in univariate analysis. Mean valuesTable 1. Clinical characteristics and in-hospital course in anemic p
myocardial infarction (STEMI).
Population
(n = 1498)
Age (y) 60.47  12.7
Age > 75 y 211 (15%)
Female gender 333 (22.2%)
Hypertension 451 (30.1%)
Diabetes mellitus 534 (35.6%)
Current smoker 1000 (66.8%)
Dyslipidemia 177 (12.1%)
Obesity 190 (12.7%)
History of HF 34 (2.3%)
History of PCI 122 (8.1%)
History of CABG 6 (0.4%)
HF on admission 331 (22.1%)
Cardiogenic shock on admission 35 (2.3%)
Renal failure on admission 116 (8.3%)
Anterior infarction 696 (46.5%)
Primary PCI 424 (28.3%)
Symptoms to primary PCI delay (h) 4.88  4.23
Thrombolysis 510 (34%)
Symptoms to thrombolysis delay (h) 3.79  4
No reperfusion therapy 564 (37.6%)
New onset atrial fibrillation 100 (6.7%)
Inotropic agents use 216 (14.4%)
Bleeding complication 41 (2.8%)
CCU length of stay (d) 4.74  3.55
In-hospital mortality 129 (8.6%)
CABG = coronary artery bypass grafting; CCU = coronary care unit; HF = he
Please cite this article in press as: Jomaa W. et al., Prevalence and prog
myocardial infarction in a Tunisian center, J Saudi Heart Assoc (2016), httof continuous variables were compared between
anemic and nonanemic patients using the Student
t test. In the four subgroup analysis, the difference
between means was evaluated using the one way
analysis of variance test. Multivariate analysis on
variables significantly associated with in-hospital
death in univariate analysis was performed using
binary logistic regression. Results are expressed as
odds ratios (OR) with accompanying 95% confi-
dence interval (95% CI). A p value <0.05 was con-
sidered significant. Statistical analyses were
performed using SPSS (SPSS Inc, Chicago, IL,
USA) version 17 for Windows.3. Results
The overall study population included 1498
patients. Five hundred and forty-four (36.3%)
patients were anemic. Prevalence of anemia was
comparable between women and men (38.4% vs.
35.7%, p = 0.36) and significantly higher in elderly
compared to younger patients (52.1% vs. 34.8%,
p < 0.001). Compared to nonanemic patients, ane-
mic patients were more likely to have a history
of arterial hypertension (p < 0.001) and diabetes
mellitus (p = 0.007) (Table 1). Conversely, theyatients versus nonanemic patients presenting for ST-elevation
Nonanemic
(n = 954)
Anemic
(n = 544)
p
58  12.5 64.71  11.83 <0.001
101 (11.5%) 110 (21%) <0.001
205 (21.5%) 128 (23.5%) 0.361
245 (25.7%) 206 (37.9%) <0.001
316 (33.1%) 218 (40.1%) 0.007
678 (71.1%) 322 (59.2%) <0.001
115 (12.2%) 62 (11.9%) 0.869
132 (13.9%) 58 (10.7%) 0.071
18 (1.9%) 16 (2.9%) 0.188
87 (9.1%) 35 (6.4%) 0.068
5 (0.5%) 1 (0.2%) 0.316
195 (20.4%) 136 (25%) 0.041
13 (1.4%) 22 (4%) 0.001
40 (4.6%) 76 (14.5%) <0.001
454 (47.6%) 242 (44.5%) 0.247
280 (29.4%) 144 (26.5%) 0.234
4.6  3.85 5.39  4.81 0.071
348 (36.5%) 162 (29.8%) 0.009
3.44  3.35 4.5  5.11 0.004
326 (34.1%) 238 (43.7%) 0.001
60 (6.3%) 40 (7.4%) 0.428
113 (11.8%) 103 (18.9%) <0.001
24 (2.5%) 17 (3.2%) 0.473
4.7  3.1 4.79  4.22 0.667
48 (5%) 81 (14.9%) <0.001
art failure; PCI = percutaneous coronary intervention.
nostic significance of anemia in patients presenting for ST-elevation
p://dx.doi.org/10.1016/j.jsha.2016.10.003
Table 2. Clinical presentation and in-hospital course in patients presenting for ST-elevation myocardial infarction (STEMI)
according to four hemoglobin level subgroups.
Group 1
HbP 16 g/dL
(n = 110)
Group 2
Hb 13.5–15.9 g/dL
(n = 600)
Group 3
Hb 11–13.4 g/dL
(n = 539)
Group 4
Hb < 11 g/dL
(n = 249)
p
Age (y) 55.35  11.05 56.88  12.48 62.77  12.15 66.52  11.67 <0.001
Age > 75 5 (4.5%) 55 (9.2%) 90 (16.7%) 65 (26.1%) <0.001
Female gender 11 (10%) 94 (15.7%) 135 (25%) 93 (37.3%) <0.001
Hypertension 19 (17.3%) 139 (23.2%) 191 (35.4%) 102 (41%) <0.001
Diabetes mellitus 35 (31.8%) 186 (31%) 201 (37.3%) 112 (45%) 0.001
Tobacco smoking 101 (91.8%) 454 (75.7%) 331 (61.4%) 114 (45.8%) <0.001
HF on-admission 29 (26.4%) 106 (17.7%) 120 (22.3%) 76 (30.5%) <0.001
Cardiogenic shock 2 (1.8%) 7 (1.2%) 11 (2%) 15 (6%) <0.001
Renal failure on admission 3 (2.7%) 23 (3.8%) 40 (7.4%) 50 (20%) <0.001
Primary PCI 31 (28.2%) 179 (29.8%) 154 (28.6%) 60 (24.1%) 0.41
Symptoms to primary PCI delay (h) 5.38  6.09 4.53  3.75 4.75  4.11 5.97  4.63 0.138
Thrombolysis 49 (44.5%) 210 (35%) 189 (35.1%) 62 (24.9%) 0.002
Symptoms to thrombolysis delay (h) 3.7  3.94 3.21  2.29 4.08  4.76 4.98  6.21 0.009
No reperfusion therapy 30 (27.3%) 211 (35.2%) 196 (36.3%) 127 (51%) 0.001
Bleeding complication 4 (3.7%) 12 (2%) 15 (2.8%) 10 (4.1%) 0.357
Inotropic agents use 16 (14.5%) 59 (9.8%) 74 (13.7%) 67 (26.9%) <0.001
CCU Length of stay (d) 4.91  2.76 4.62  3.05 4.72  3.4 4.98  5.11 0.626
In-hospital mortality 7 (6.4%) 21 (3.5%) 46 (8.5%) 55 (22.1%) <0.001
CCU = coronary care unit; Hb = hemoglobin; PCI = percutaneous coronary intervention.
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Regarding clinical presentation, anemic patients
were more likely to experience HF (p = 0.041),
renal failure (p < 0.001), and cardiogenic shock
(p = 0.001) on admission. No statistical difference
could be reported regarding pPCI use as the
reperfusion option for STEMI between anemic
and nonanemic patients. By contrast, recourse to
thrombolysis was significantly lower in the anemic
group (29.8% vs. 36.5%, p = 0.009). Likewise, mean
delay between symptoms onset and thrombolysis
was significantly longer. Recourse to inotropic
agents was more frequent in anemic patients,
whereas no difference in the occurrence of bleed-
ing complications was noticed between the two
groups. Anemia was associated with a signifi-
cantly higher in-hospital mortality rate (14.9% vs.
5% in nonanemic patients, p < 0.001).Table 3. Relevant factors associated wit
severe anemia presenting for ST-elevatio
univariate analysis.
Surv
Female gender 69 (3
Age < 75 y 49 (2
Hypertension 73 (3
Diabetes mellitus 83 (4
HF on admission 47 (2
Renal failure on admission 27 (1
Primary PCI 40 (2
New onset atrial fibrillation 15 (7
HF = heart failure; PCI = percutaneous corona
Please cite this article in press as: Jomaa W. et al., Prevalence and prog
myocardial infarction in a Tunisian center, J Saudi Heart Assoc (2016), httInvestigating population clinical characteristics
and outcomes according to baseline hemoglobin
levels (Table 2) revealed a gradual increase in
mean age with lower hemoglobin levels. Preva-
lence of elderly, female gender, hypertension,
and diabetes was significantly higher in the lower
hemoglobin subgroups. A progressive increase in
the occurrence of HF and cardiogenic shock upon
presentation was noted in lower hemoglobin sub-
groups and so was the recourse to inotropic agents
use. No significant ascending or descending trend
for bleeding complications occurrence or in the
mean coronary care unit length of stay could be
seen across the hemoglobin level spectrum. In-
hospital mortality was by far the highest (22.1%)
in the severe anemia subgroup (hemoglobin
<11 g/dL) compared to 6.4% (in the hemoglobin
P16 g/dL subgroup), 3.5% (in the hemoglobinh in-hospital death in patients with
n myocardial infarction (STEMI) in
iving Dead p
5.6%) 24 (43.6%) 0.275
5.3%) 16 (29.1%) 0.568
7.6%) 29 (52.7%) 0.044
2.8%) 29 (52.7%) 0.191
4.2%) 29 (52.7%) <0.001
4.8%) 23 (41.8%) <0.001
0.6%) 20 (36.4%) 0.016
.7%) 10 (18.2%) 0.023
ry intervention.
nostic significance of anemia in patients presenting for ST-elevation
p://dx.doi.org/10.1016/j.jsha.2016.10.003
Table 4. Factors independently associated with in-hospital
death in patients with severe anemia presenting for ST-
elevation myocardial infarction (STEMI) in multivariate
analysis.
Variable Odds ratio 95% CI p
Hypertension 1.66 0.83–3.29 0.148
Diabetes mellitus 1.3 0.64–2.60 0.458
HF on admission 3.42 1.73–6.74 <0.001
Renal failure on admission 3.82 1.83–7.96 <0.001
Primary PCI 0.45 0.21–0.93 0.033
New onset atrial fibrillation 0.44 0.16–1.2 0.112
CI = confidence interval; HF = heart failure; PCI = percutaneous coro-
nary intervention.
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ANEMIA IN STEMI13.5–15.9 g/dL subgroup), and 8.5% (in the hemo-
globin 11–13.4 g/dL subgroup). In the severe ane-
mia subgroup, 34 (61.8%) patients died from
cardiogenic shock or refractory pulmonary edema,
seven (12.8%) from refractory ventricular arrhyth-
mia, three (5.4%) from mechanical complications,
and the remaining from noncardiac causes.
In the severe anemia subgroup, clinical and
prognostic factors relevant to in-hospital mortality
were studied (Table 3). In univariate analysis,
factors significantly associated with in-hospital
mortality in patients with severe anemia were
hypertension (p = 0.044), HF on admission
(p < 0.001), renal failure on admission (p < 0.001),
new onset atrial fibrillation (p = 0.023), and pPCI
as a reperfusion strategy (p = 0.016). Multivariate
analysis performed on this model showed that fac-
tors independently associated with in-hospital
death were HF on admission (OR = 3.42, 95% CI:
1.73–6.74, p < 0.001), and renal failure on admis-
sion (OR = 3.82, 95% CI: 1.83–7.96, p < 0.001). The
absence of pPCI use as the reperfusion option
was independently associated with in-hospital
death in multivariate analysis (OR = 2.22, 95% CI:
1.07–4.76, p = 0.033) (Table 4).4. Discussion
This is an original study performed in a North
African country that clearly highlights the prog-
nostic impact of baseline anemia in patients pre-
senting for ACS and in particular acute STEMI.
Furthermore, the study emphasizes the heavy
prognostic impact of clinical presentation in
severely anemic patients and the beneficial effect
of pPCI in these critically ill patients.
In the present study, prevalence of anemia in
patients presenting for STEMI was 36.3%. This
rate is considerably higher than those reported
in western series. Al Falluji et al. [1] reported a
prevalence of 10.2% in a large American databasePlease cite this article in press as: Jomaa W. et al., Prevalence and prog
myocardial infarction in a Tunisian center, J Saudi Heart Assoc (2016), httfrom New Jersey and Tsujita et al. [4] found simi-
lar rates in the Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trial [4]. In the Mid-
dle Eastern Gulf RACE II registry [15], this preva-
lence rose to 28% in patients presenting for ACS
but remained lower than that reported in our
study.
The impact that anemia has on in-hospital
course in patients presenting for STEMI has been
confirmed in several studies and irrespectively of
the antithrombotic regimens and reperfusion
modalities used [4,16,17]. Results from the present
study regarding the harmful effect of anemia in
these patients are in accordance with those
reported elsewhere. Such an effect could be due
to anemia itself, but also to other comorbid condi-
tions classically associated with it that could
aggravate the former effect or be a confounding
factor such as renal failure. Likewise, the prognos-
tic significance of low baseline hemoglobin levels
was consistent in a variety of demographic groups
and clinical settings. Kitai et al. [18] demonstrated
an impact of low hemoglobin levels on mortality
in patients undergoing pPCI that was maintained
even for those with mild anemia. In the same
study, a concomitant CKD was associated with
significantly higher incidence of major cardiovas-
cular events. In our study, the relationship
between baseline hemoglobin level and the occur-
rence of HF or cardiogenic shock upon presenta-
tion was obvious. Recourse to inotropic agents
had also the same trend. In the Optimal Trial in
Myocardial Infarction with the Angiotensin II
Antagonist Losartan (OPTIMAAL), anemia was
associated with HF on presentation and there
was a clear trend to higher Killip classes in STEMI
with lower hemoglobin levels [19]. In a study car-
ried out in 2310 patients presenting for ACS in the
United Kingdom, Archbold et al. [6] identified
anemia as a powerful determinant of clinically
diagnosed left ventricular dysfunction occurrence
with the highest rates in STEMI and for the lowest
hemoglobin categories. In another report, on top
of being predictive of overall mortality, anemia
was also predictive of mortality from noncardiac
causes in young patients [20].
In-hospital mortality rate was significantly
higher in anemic patients in comparison to
nonanemic ones and was particularly high in
patients with severe anemia (22.1%). This fact
could be demonstrated in several reports, but in
our study, the in-hospital mortality rate in anemic
patients is generally higher. In our context, these
patients have a higher prevalence of traditionalnostic significance of anemia in patients presenting for ST-elevation
p://dx.doi.org/10.1016/j.jsha.2016.10.003
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ties when compared to Western populations,
which could partly explain such a disparity in
outcomes.
There are several pathophysiological explana-
tions to the worse clinical outcome and mortality
in patients suffering from coronary artery disease
and anemia. In anemic patients, there is a signifi-
cant reduction of oxygen supply to the myocar-
dium in addition to the impaired coronary blood
flow. Other mechanisms include tachycardia and
decrease in blood viscosity [21]. Eventually,
recourse to blood transfusion in anemic patients
with or without hemorrhagic complications was
proven to be a powerful predictor of worse out-
come in the whole ACS spectrum [9].
In our current practice, reperfusion strategies
(i.e., thrombolysis and pPCI) were not equally uti-
lized according to hemoglobin subgroups. While
there was a significant trend to less thrombolysis
use in patients with lower baseline hemoglobin
levels, pPCI was equally used in the different sub-
groups. This propensity to a lesser recourse to
reperfusion therapies in anemic patients was fre-
quently reported in the literature [22,23]. Opera-
tors often prefer not to opt for an invasive
procedure or hemorrhage-inducing pharmacolog-
ical therapeutic in patients at risk of bleeding. In
our study, in patients with severe anemia, the
use of pPCI as the reperfusion option was associ-
ated with a worse in-hospital outcome in univari-
ate analysis. In our context, the decision to
perform (or not) a pPCI is left to the discretion
of the operator, and in all likelihood this led to a
subpopulation with a critical clinical presentation
and outcome. Nonetheless and interestingly, this
observation was reversed when pPCI was
included in a multivariate model where its effect
on in-hospital mortality was adjusted to main
variables associated with the latter outcome. This
is a highly informative result given that it empha-
sizes the beneficial effect of pPCI in STEMI even
for patients suffering from severe anemia for
whom such a procedure could be considered haz-
ardous at a first glance.4.1. Study limitations
Although very informative about our current
practice, the present study was performed on data
that were collected retrospectively in a periodical
manner and the results have to be interpreted
very cautiously. No randomization was carried
out and compared subgroups cannot perfectly
match regarding all variables linked with risk pro-
file and prognosis. Results certainly cannot bePlease cite this article in press as: Jomaa W. et al., Prevalence and prog
myocardial infarction in a Tunisian center, J Saudi Heart Assoc (2016), httextrapolated to the whole Tunisian population
given that the study was performed on a near
exclusively urban population. Another study limi-
tation is the absence of relation between the
hemoglobin levels and the occurrence of hemor-
rhagic events during hospital stay. Indeed, preva-
lence of bleeding complications was low and
statistical significance precisely in this topic could
probably be reached in a larger study population.5. Conclusion
The present study issued from a single center
registry confirms the high prevalence of anemia
in patients presenting for STEMI in the Tunisian
context. In these patients, low baseline hemoglo-
bin levels were significantly associated with worse
in-hospital outcomes. In patients with severe ane-
mia, initial clinical presentation was very impact-
ful on in-hospital outcomes and the absence of
pPCI use as a reperfusion therapy was indepen-
dently associated with in-hospital death.
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